🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.

RecruitingNAAges 50 Years - 70 YearsAllQing Su
NCT06907329 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 50-70 years with overweight or obesity (BMI 24kg/m2); 2. At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \<7% without glucose-lowering drug therapy; 3. Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form. Exclusion Criteria: 1. Patients with tumours; 2. Patients with autoimmune diseases (excluding Hashimoto's thyroiditis); 3. Severe cardiovascular disease or cardiac insufficiency; 4. Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg; 5. Chronic obstructive pulmonary disease; 6. Chronic active hepatitis or cirrhosis; 7. Chronic renal insufficiency; 8. Stroke patients 9. Severe haematological diseases; 10. Infectious diseases; 11. Mental illness; 12. Other conditions that, in the opinion of the investigator, may affect the results of the study; 13. Those who have used NMN or other anti-aging agents within six months. 14. Premenopausal woman 15. ALT, AST values are more than three times higher than the upper limit of the normal reference range
💊

What it tests

  • NMN
  • Placebo
📍

Where

1 site
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy